6-K 1 tekmira6k_07072011.htm tekmira6k_07072011.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
___________________
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of, July 2011
 
Commission File Number: 001-34949
 
___________________
 
Tekmira Pharmaceuticals Corporation
(Translation of registrant's name into English)
 
100-8900 Glenlyon Parkway
Burnaby, British Columbia
Canada, V5J 5J8
 (Address of principal executive offices)
___________________
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F þ                                          Form 40-F o
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)  o
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)  o
 

 
 
 
 
 
 
INCORPORATION BY REFERENCE

Exhibit 99.1 to this Form 6-K is hereby incorporated by reference as an exhibit to the registration statement on Form F-10 (File No. 333-169311) of Tekmira Pharmaceuticals Corporation.

 
DOCUMENTS FILED AS PART OF THIS FORM 6-K

See the Exhibit Index hereto.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
   Tekmira Pharmaceuticals Corporation
   
 Date:  July 7, 2011 By:  /s/ Ian C. Mortimer            
  Name:  Ian C. Mortimer
  Title: 
Executive Vice President and Chief Financial Officer
   
 
 
 
 
 

 

EXHIBIT INDEX
 
 

Exhibit
Description
   
99.1
Material Change Report, dated July 7, 2011
99.2 Report of Voting Results